Splenic Infarction in Patients with Philadelphia-negative Myeloproliferative Neoplasms

Intern Med. 2022 Dec 1;61(23):3483-3490. doi: 10.2169/internalmedicine.9124-21. Epub 2022 May 7.

Abstract

Objective We retrospectively analyzed the prevalence and clinical features of splenic infarctions in patients with Philadelphia chromosome-negative myeloproliferative neoplasms (Ph- MPNs). Patients Patients diagnosed with essential thrombocythemia (ET), polycythemia vera (PV), prefibrotic/early primary myelofibrosis (pre-PMF), or PMF from January 1996 to October 2020 in Chungnam National University Hospital, Daejeon, Korea, were reviewed. Results A total of 347 patients (143 ET, 129 PV, 44 pre-PMF, and 31 PMF patients; 201 men and 146 women) with a median age of 64 (range 15-91) years old were followed up for a median of 4.7 (range 0.1-26.5) years. Fifteen (4.3%) patients exhibited splenic infarctions at the diagnosis. These were most common in PMF patients (12.9%), followed by pre-PMF (9.1%) and PV (5.4%) patients. Multifocal infarcts (60.0%) were most common, followed by solitary (33.3%) and extensive infarcts (6.7%). The cumulative incidence of thrombosis in patients with splenic infarctions tended to be higher than in those lacking infarctions (10-year incidence 46.7% vs. 21.0% in PV; p=0.215; 33.3% vs. 17.9% in pre-PMF; p=0.473) patients, but statistical significance was lacking. Palpable splenomegaly (hazard ratio 14.89; 95% confidence interval 4.00-55.35; p<0.001) was the only independent risk factor for splenic infarction. During follow-up, 5 (1.4%) patients developed splenic infarctions. Conservative treatment adequately controlled the symptoms; no serious complications were noted in any patient. Conclusion Splenic infarctions occurred most frequently in patients with PMF; it was rare in patients with ET. The clinical courses were generally mild.

Keywords: essential thrombocythemia; myeloproliferative neoplasm; polycythemia vera; primary myelofibrosis; splenic infarction.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Female
  • Humans
  • Male
  • Middle Aged
  • Mutation
  • Myeloproliferative Disorders* / complications
  • Myeloproliferative Disorders* / epidemiology
  • Polycythemia Vera* / complications
  • Polycythemia Vera* / diagnosis
  • Polycythemia Vera* / epidemiology
  • Retrospective Studies
  • Splenic Infarction* / epidemiology
  • Splenic Infarction* / etiology
  • Thrombocythemia, Essential* / complications
  • Thrombocythemia, Essential* / diagnosis
  • Thrombocythemia, Essential* / epidemiology
  • Young Adult